Article Title

Intraoperative radiotherapy for early breast cancer – Authors' reply


We were delighted by the interest generated after the publication of the TARGIT-A trial results and are happy to provide clarifications and reassurance.

First, we wish to re-emphasise that the TARGIT-A trial compared “bespoke” radiotherapy—ie, the risk-adjusted approach of TARGIT (with added whole-breast external-beam radiotherapy depending on the individual risk) versus whole-breast external-beam radiotherapy for all. Overall, 14% of patients who received TARGIT also received external-beam radiotherapy. Of those who received TARGIT at the time of the first operation, 21% (141/669) received external-beam radiotherapy. Although nearly 80% of such patients did not have any further radiotherapy, we emphasise that this approach is implicit in the TARGIT-A protocol, which allowed addition of external-beam radiotherapy when indicated, rather than TARGIT as the only treatment in every patient. This pragmatic approach matches what clinicians should do in the real world.



Find in your library



Link to Publisher Version (DOI)